Related Experiment Video
Updated: Jul 26, 2026
Isolation and Enrichment of Human Adipose-derived Stromal Cells for Enhanced Osteogenesis
Published on: January 12, 2015
Differences in the Osteogenic Differentiation Capacity of Omental Adipose-Derived Stem Cells in Obese Patients With
Wilfredo Oliva-Olivera1, Antonio Leiva Gea1, Said Lhamyani1
1Department of Clinical Endocrinology and Nutrition (W.O.-O., S.L., L.C.-A., J.A.T., R.E.B., F.J.T.), Institute of Biomedical Research of Malaga, Hospital Complex of Malaga (Virgen de la Victoria), University of Malaga, and Department of Orthopedic Surgery and Traumatology (A.L.G.), Virgen de la Victoria University Hospital and University of Malaga, and Department of Internal Medicine (M.R.B.-L.), Regional University Hospital of Malaga, Institute of Biomedical Research of Malaga, 29010 Malaga, Spain; Centro de Investigación Biomédica en Red of Obesity Physiopathology and Nutrition (W.O.-O., S.L., L..C.-A., J.A.T., M.R.B.-L., R.E.B., F.J.T.), and Centro de Investigación Biomédica en Red of Diabetes and Associated Metabolic Disorders (S.F.-V.), Institute of Health Salud Carlos III, 28029 Madrid, Spain; Department of Endocrinology and Nutrition (P.P.G.L.) and Unit of Innovation in Minimally Invasive Surgery (S.M.C.), Department of Surgery, Virgen del Rocío University Hospital, 41013 Seville, Spain; and University Hospital of Tarragona Joan XXIII Institut d'Investigació (S.F.-V.), Sanitaria Pere Virgili, Universitat Rovirai Virgili, 43003 Tarragona, Spain.
Abstract:
Multiple studies have suggested that the reduced differentiation capacity of multipotent adipose tissue-derived mesenchymal stem cells (ASCs) in obese subjects could compromise their use in cell therapy. Our aim was to assess the osteogenic potential of omental ASCs and to examine the status of the isolated CD34(negative)-enriched fraction of omental-derived ASCs from subjects with different metabolic profiles. Omental ASCs from normal-weight subjects and subjects with or without metabolic syndrome were isolated, and the osteogenic potential of omental ASCs was evaluated. Additionally, osteogenic and clonogenic potential, proliferation rate, mRNA expression levels of proteins involved in redox balance, and fibrotic proteins were examined in the CD34(negative)-enriched fraction of omental-derived ASCs. Both the omental ASCs and the CD34(negative)-enriched fraction of omental ASCs from subjects without metabolic syndrome have a greater osteogenic potential than those from subjects with metabolic syndrome. The alkaline phosphatase and osteonectin mRNA were negatively correlated with nicotinamide adenine dinucleotide phosphate oxidase-2 mRNA and the mRNA expression levels of the fibrotic proteins correlated positively with nicotinamide adenine dinucleotide phosphate oxidase-5 mRNA and the homeostasis model assessment. Although the population doubling time was significantly higher in subjects with a body mass index of 25 kg/m(2) or greater, only the CD34(negative)-enriched omental ASC fraction in the subjects with metabolic syndrome had a higher population doubling time than the normal-weight subjects. The osteogenic, clonogenic, fibrotic potential, and proliferation rate observed in vitro suggest that omental ASCs from subjects without metabolic syndrome are more suitable for therapeutic osteogenic applications than those from subjects with metabolic syndrome.
